Category - Feature

Feature

Matinas BioPharma moves focus to anti-infectives

By Len Zehr After moving a novel omega-3 program through a successful Phase 2 program, Matinas BioPharma Holdings (OTCQB:MTNB) is now advancing two anti-infective drug candidates in the war against drug resistance. “Our...

July 28, 2015

Feature

Xenon still committed to TV-45070 for neuropathic pain

By Len Zehr Xenon Pharmaceuticals (NASDAQ:XENE) and its development and commercialization partner, Teva Pharmaceutical Industries (NYSE, TASE:TEVA), remain fully committed to the development of TV-45070 for neuropathic...

July 21, 2015

Feature

In conversation with Heather Morehouse Ettinger

By Len Zehr As a partner in the law firm of Troutman Sanders LLP, Heather Morehouse Ettinger focuses her practice on intellectual property due diligence and transaction drafting, intellectual property litigation, and...

July 14, 2015

Feature

M Pharma advancing technologies for obesity and diabetes

By Len Zehr M Pharmaceutical (OTCQB:MPHMF; CSE:MQ; FWB:T3F1.F) is advancing a family of biomedical technologies to manage obesity – TriMeo and TriMtec – and eMosquito to manage diabetes. “All three of our technologies...

July 7, 2015

Feature

Regenicin readying clinical trials of NovaDerm skin substitute

By Len Zehr Regenicin (OTC:RGIN) is completing validation of its NovaDerm skin substitute at a leading institute of technology in the U.S and plans to seek FDA approval to move into clinical trials in the second half of...

June 30, 2015

Feature

Inogen POCs represent paradigm shift in oxygen therapy

By Len Zehr Inogen (NASDAQ:INGN) is continuing to convert patients with lung disease from bulky oxygen tanks that need to be refilled every two weeks to its lightweight, portable oxygen concentrator (POC) that...

June 16, 2015

Feature

Titan Pharma Phase 3 data validate ProNeura technology

Titan Pharmaceuticals’ (OTCQB:TTNP) positive topline results from a Phase 3 clinical study of Probuphine, its subdermal implant of buprenorphine for the long-term maintenance treatment of opioid addiction, validate the...

June 9, 2015

Feature

KAHR Medical on financing trail to develop dual signaling proteins

By Len Zehr Closely-held KAHR Medical of Israel is seeking to raise* as much as $10-million in the U.S. and Europe to continue development of its dual signaling proteins (DSPs), including KAHR-102, its lead drug...

June 2, 2015

Feature

Profound Medical seeking CE Mark for TULSA-PRO this year

Profound Medical, which is going public next week, figures that data from a 30-patient safety and feasibility study of its transurethral ultrasound ablation (TULSA) technology for minimally invasive treatment of...

May 26, 2015

Feature

Provectus taking novel path to treat cancer

By Len Zehr Rather than taking a biochemistry approach to develop drugs that kill cancer cells, Provectus Biopharmaceuticals (NYSE MKT:PVCT) is using physical chemistry by harnessing the unique properties of Rose...

May 19, 2015

Category - Feature

Subscribe